I[ntroduction]{.smallcaps} {#sec1-1}
==========================

The prevalence of atrial fibrillation (AF) will increase rapidly in the next few decades due to population aging and longer survival. AF confers a 5-fold increase in stroke risk and 2-fold increase in cardiac mortality.\[[@ref1][@ref2]\] Moreover, the risk of stroke is high in any type of AF.\[[@ref3]\] To identify the risk for stroke in patients with nonvalvular AF (NVAF), the CHADS~2~ and CHA~2~DS~2~-VASc scores are commonly used in clinical practice.\[[@ref4][@ref5]\] However, their predictive powers remain limited in patients with low CHADS~2~ or CHA~2~DS~2~-VASc score.\[[@ref6]\]

Metabolic syndrome (MS) is a cluster of common clinical disorders, including obesity, insulin resistance, glucose intolerance, hypertension, and dyslipidemia, which is a risk factor of cardiovascular disease. MS can lead to vascular endothelial dysfunction, activation of coagulatory and inflammatory reactions, and subclinical damage in various organs, which are more severe than the harm caused by conventional risk factors.\[[@ref7]\] Recently, a study indicated that MS was associated with thromboembolic risk of AF, and CHADS~2~-MS score was superior to CHADS~2~ score in predicting the risk of AF-related stroke.\[[@ref8]\] Hence, MS may be a supplement of CHADS~2~ score for predicting AF-related stroke.

Clinically, left atrial or LA appendage (LA/LAA) thrombus provides objective evidence of AF-related stroke in several studies,\[[@ref9][@ref10]\] and it is used as a surrogate marker of potential stroke for the NVAF patients.\[[@ref6]\] However, it is uncertain whether MS is also linked to LA/LAA thrombus in patients with low CHADS~2~ and CHA~2~DS~2~-VASc scores. In this study, we sought to investigate the effect of MS on risk stratification of LA/LAA thrombus formation in NVAF patients.

M[ethods]{.smallcaps} {#sec1-2}
=====================

Study population {#sec2-1}
----------------

This study included 400 consecutive patients with symptomatic NVAF in the Sun Yat-Sen Memorial Hospital of the Sun Yat-Sen University from 2007 to 2014, and finally, 294 patients were enrolled according to the inclusion and exclusion criteria. AF was diagnosed by 12-lead electrocardiogram or 24-h dynamic electrocardiogram. All the patients underwent transesophageal echocardiography (TEE) examination to detect LA/LAA thrombi. Exclusion criteria included acute myocardial infarction within previous 6 months, rheumatic heart disease or valvular heart disease, a history of cardiac surgery (e.g., coronary artery bypass graft and heart valve replacement), hyperthyroidism, cancer, end-stage renal disease, and gastroesophageal diseases, which are contraindications to TEE examination. As medicine may affect the thrombus formation and the diagnosis of MS, anyone who had received antiplatelet or anticoagulation agents (e.g., aspirin, clopidogrel, warfarin, dabigatran, rivaroxaban, and apixaban) and lipid-lowering drugs (e.g., statins, fibrates, nicotinic acid, bile acid sequestrants) were also excluded from the study. The study was approved by the hospital\'s Ethics Committee, and informed consent was obtained from all patients.

Metabolic syndrome definition {#sec2-2}
-----------------------------

MS was defined according to the 2009 MS harmonizing definition and the guidelines issued by the Chinese Diabetes Society of the Chinese Medical Association as having three or more of the following: (1) body mass index (BMI) ≥28 kg/m^2^, (2) fasting triglyceride (TG) ≥150 mg/dl, (3) fasting high-density lipoprotein cholesterol (HDL-C) \<40 mg/dl, (4) systolic blood pressure ≥130 mmHg/diastolic blood pressure ≥85 mmHg and/or a history of hypertension treatment, and (5) fasting glucose ≥100 mg/dl or a history of diabetes (or on diabetes medication).\[[@ref11][@ref12]\]

Transthoracic echocardiography and transesophageal echocardiography examination {#sec2-3}
-------------------------------------------------------------------------------

All patients underwent transthoracic echocardiography with a GE VIVID 7 ultrasonograph and a 2.5-MHz transducer in a left lateral decubitus position before TEE examination. The LA diameter (LAD) and left ventricular end-diastolic diameter were obtained from M-mode tracing, and the left ventricular ejection fraction (LVEF) was calculated. TEE was performed with a 5-MHz multiplane probe, and live images were analyzed by an experienced physician who was blind to lipid levels. Continuous images of the LA and LAA were assessed to determine the presence or absence of thrombus. LA/LAA thrombus was defined as a well-circumscribed echogenic mass with a unique echotexture contrasting with the adjacent myocardium.

CHADS~2~, CHA~2~DS~2~-VASc, MS, CHADS~2~-MS, CHA~2~DS~2~-VASc-MS scores, and clinical evaluation {#sec2-4}
------------------------------------------------------------------------------------------------

In this study, both CHADS~2~ and CHA~2~DS~2~-VASc scores were used as the same in the 2010 ESC guideline.\[[@ref6]\] Patients with CHADS~2~ or CHA~2~DS~2~-VASc score of 0, 1, and ≥2 were divided into low-, moderate-, and high-risk stroke groups, respectively. In addition, the MS score was calculated as the number of abnormal items in the MS criteria, and the total score ranged from 0 to 5. CHADS~2~ score and MS score overlapped in high blood pressure (HBP) and diabetes mellitus (DM); therefore, CHADS~2~-MS score was the combination of CHADS~2~ score and additional MS score which removed HBP and DM components. Similarly, CHA~2~DS~2~-VASc-MS was composed of CHA~2~DS~2~-VASc score and additional MS score which removed HBP and DM components.

Clinical data consisted of clinical status (e.g., age, gender, BMI, type of AF, HBP, DM, previous stroke/transient ischemic attack \[TIA\], vascular disease, and MS), medication history, electrocardiograms, echocardiograms, TEE, and blood sample results. Hypertension was defined as systolic blood pressure \>140 mmHg or diastolic blood pressure \>90 mmHg. DM was defined as the use of diabetic medications or fasting blood glucose \>126 mg/dl. Chronic heart failure was defined as systolic heart failure or LVEF \<40%. Previous and current stroke was confirmed by brain computed tomography and magnetic resonance imaging. Vascular disease was defined as atherosclerotic disease (diagnosed by vascular angiogram or ultrasonography).

Statistical analysis {#sec2-5}
--------------------

Continuous variables are presented as mean ± standard deviation or median (Q~1~, Q~3~), and categorical variables are presented as numbers and proportions. The differences between two groups were compared using independent samples *t*-test for normal distributed data and Mann--Whitney *U*-tests for non-normal distributed data. Discrete variables between two groups were compared using Chi-square test or Fisher\'s exact test. Logistic regression analyses were performed to determine which variables were significantly related to LA/LAA thrombus. Results of the logistic regression were reported as odds ratios (*OR*s) and corresponding 95% confidence intervals. All the variables which were statistically significant at the 0.05 level in univariate analyses were entered into a multivariate logistic regression model with forward step-wise selection. At each step, the variable was entered at the 0.05 level and removed at the 0.10 level. For all scores, the relationships between risk scores or categories and the prevalence of LA/LAA thrombus were examined using Chi-square test. Receiver operating characteristic (ROC) curves were constructed, and C-statistics was measured for each score to compare the predictive powers for the risk of LA/LAA thrombus formation. Youden index (*J*) was calculated using the following formula: *J* = sensitivity + specificity − 1, and the maximum values of Youden index for each score system were calculated to determine the corresponding optimal cutoff points. PASW Statistics version 18.0 (SPSS Inc., Chicago, Illinois, USA) was used in data analysis. All probability values were two-sided, and *P* \< 0.05 was considered statistically significant.

R[esults]{.smallcaps} {#sec1-3}
=====================

Baseline characteristics of patients with and without left atrial/left atrial appendage thrombi {#sec2-6}
-----------------------------------------------------------------------------------------------

For all the 294 patients enrolled in this study, the median of CHADS~2~ score and CHA~2~DS~2~-VASc score was 1.2 and 2.3, respectively. Fifty-six patients had LAA thrombi and 64 patients were diagnosed with MS. In 56 patients with LAA thrombus, there were 9, 19, and 28 patients with CHADS~2~ score of 0, 1, and ≥2, and 3, 11, and 42 patients with CHA~2~DS~2~-VASc score of 0, 1, and ≥2, respectively. The baseline characteristics of the patients were listed in [Table 1](#T1){ref-type="table"}. Compared with patients without thrombi, patients with LA/LAA thrombi were elder (63.8 years vs. 60.6 years, *P* = 0.042), and had higher proportions of congestive heart failure (CHF) (10.7% vs. 1.7%, *P* = 0.004), HBP (75.0% vs. 42.4%, *P* \< 0.001), DM (35.7% vs. 12.2%, *P* \< 0.001), previous stroke/TIA (35.7% vs. 10.5%, *P* \< 0.001), vascular disease (46.4% vs. 28.6%, *P* = 0.011), and MS (57.1% vs. 13.4%, *P* \< 0.001). In addition, higher BMI, larger LAD, higher serum levels of lipids (TG, total cholesterol \[TC\], and low-density lipoprotein cholesterol \[LDL-C\]), lower HDL-C, and estimated glomerular filtration rate were found in patients with LA/LAA thrombi. Furthermore, individuals with thrombi tended to have higher risk scores of CHADS~2~, CHA~2~DS~2~-VASc, MS, CHADS~2~-MS, and CHA~2~DS~2~-VASc-MS (*P* \< 0.001 for all).

###### 

Baseline characteristics of patients with and without LA/LAA thrombus

  Variables                         Thrombi (+) (*n* = 56)   Thrombi (−) (*n* = 238)   Statistics   *P*
  --------------------------------- ------------------------ ------------------------- ------------ ---------
  Demographic data                                                                                  
   Age, years                       63.8 ± 10.4              60.6 ± 10.5               2.041\*      0.042
   Male, *n* (%)                    36 (64.3)                146 (61.3)                0.166^†^     0.761
   BMI, kg/m^2^                     26.3 ± 3.9               24.3 ± 3.4                3.375\*      \<0.001
   Paroxysmal AF, *n* (%)           44 (78.6)                189 (79.3)                0.019^†^     1.000
   Chronic heart failure, *n* (%)   6 (10.7)                 4 (1.7)                   8.678^‡^     0.004
   Hypertension, *n* (%)            42 (75.0)                101(42.4)                 19.242^†^    \<0.001
   Diabetes mellitus, *n* (%)       20 (35.7)                29 (12.2)                 18.071^†^    \<0.001
   Previous stroke/TIA, *n* (%)     20 (35.7)                25 (10.5)                 22.225^†^    \<0.001
   Vascular diseases, *n* (%)       26 (46.4)                68 (28.6)                 6.646^†^     0.011
   Metabolic syndrome, *n* (%)      32 (57.1)                32 (13.4)                 50.830^†^    \<0.001
   CHADS~2~ score                   1.5 (1.0,4.0)            1.0 (0,1.0)               5.572^§^     \<0.001
   CHA~2~DS~2~-VASc score           3.0 (1.5,5.0)            2.0 (1.0,3.0)             4.981^§^     \<0.001
   MS score                         3.0 (1.5,4.0)            1.0 (0,2.0)               6.627^§^     \<0.001
   CHA~2~DS~2~-MS score             3.5 (2.0,4.0)            1.0 (0,2.0)               7.307^§^     \<0.001
   CHA~2~DS~2~-VASc-MS score        5.0 (3.0,6.0)            2.0 (1.0,3.0)             6.892^§^     \<0.001
  Clinical data                                                                                     
   LVEF, %                          67.5 (61.0,71.0)         67.0 (64.0,71.0)          0.498^§^     0.620
   LA diameter, mm                  39.0 (36.0,42.0)         35.0 (32.0,39.0)          5.191^§^     \<0.001
   LVEDD, mm                        48.5 (45.5,52.0)         48.0 (45.0,50.0)          1.424^§^     0.155
   TG, mg/dl                        150.5 (118.7,221.4)      114.7 (87.7,154.1)        4.376^§^     \<0.001
   TC, mg/dl                        193.9 (167.8,219.7)      176.9 (157.8,202.2)       2.636^§^     0.008
   HDL-C, mg/dl                     42.0 (35.0,50.3)         46.8 (41.0,52.6)          2.814^§^     0.005
   LDL-C, mg/dl                     127.2 (110.8,144.1)      111.0 (94.4,128.4)        3.664^§^     \<0.001
   eGFR, ml/min                     62.9 (53.4,70.0)         73.0 (62.2,84.6)          4.625^§^     \<0.001
  Medication before TEE, *n* (%)                                                                    
   β-blockers                       16 (32.7)                69 (28.2)                 0.004^†^     0.950
   ACEIs/ARBs                       29 (51.8)                60 (25.2)                 15.168^†^    \<0.001
   CCBs                             14 (25.0)                36 (15.1)                 3.131^†^     0.112

Values are present by mean ± standard deviation or median (Q1, Q3), or number (percentages). \*: Independent samples *t*-test; ^†^: Chi square test; ^‡^: Fisher\'s test, ^§^: Nonparametric test. LA: Left atrial; LAA: Left atrial appendage; BMI: Body mass index; AF: Atrial fibrillation; TIA: Transient ischemic attack; MS: Metabolic syndrome; LVEF: Left ventricular ejection fraction; LVEDD: Left ventricular end-diastolic diameter; TG: Triglyceride; TC: Total cholesterol; HDL-C: High density lipoprotein cholesterol; LDL-C: Low density lipoprotein cholesterol; ACEIs: Angiotensin converting enzyme inhibitors; ARBs: Angiotensin receptor blockers. CCBs: Calcium channel blockers.

Risk factors of the left atrial/left atrial appendage thrombus formation {#sec2-7}
------------------------------------------------------------------------

The results of univariate and multivariate logistic regression analyses were shown in [Table 2](#T2){ref-type="table"}. Age ≥75 years (*OR* = 3.882, *P* = 0.002), BMI ≥28 kg/m^2^ (*OR* = 3.576, *P* \< 0.001), CHF (*OR* = 7.020, *P* = 0.003), HBP (*OR* = 4.069, *P* \< 0.001), DM (*OR* = 4.004, *P* \< 0.001), previous stroke/TIA (*OR* = 2.176, *P* \< 0.001), LA \>35 mm (*OR* = 4.335, *P* \< 0.001), TG ≥150 mg/dl (*OR* = 2.778, *P* = 0.001), HDL-C \<40 mg/dl (*OR* = 2.815, *P* = 0.001), CHADS~2~ score ≥2 (*OR* = 8.628, *P* \< 0.001), CHA~2~DS~2~-VASc score ≥2 (*OR* = 4.472, *P* = 0.016), and MS score ≥3 (*OR* = 23.000, *P* \< 0.001) were associated with LA/LAA thrombus formation.

###### 

Univariate and multivariate logistic regression model of LA/LAA thrombus with AF

  Variables                Univariate               Multivariate                            
  ------------------------ ------------------------ -------------- ------------------------ ---------
  Age, years                                                                                
   65--74                  1.269 (0.655--2.459)     0.480          --                       --
   ≥75                     3.882 (1.661--9.074)     0.002          --                       --
  Male                     1.134 (0.619--2.079)     0.684          --                       --
  BMI ≥28 (kg/m^2^)        3.576 (1.846--6.929)     \<0.001        --                       --
  Chronic heart failure    7.020 (1.910--25.797)    0.003          --                       --
  Hypertension             4.069 (2.109--7.851)     \<0.001        --                       --
  DM                       4.004 (2.048--7.829)     \<0.001        --                       --
  Previous stroke/TIA      2.176 (1.544--3.066)     \<0.001        1.991 (1.332--2.977)     0.001
  LA \>35 (mm)             4.335 (2.216--8.483)     \<0.001        2.823 (1.317--6.051)     0.008
  TG ≥150 (mg/dl)          2.778 (1.528--5.050)     0.001          --                       --
  HDL-C \<40 (mg/dl)       2.815 (1.531--5.175)     0.001          --                       --
  CHADS~2~ score                                                                            
   1                       1.794 (0.713--4.516)     0.214          --                       --
   ≥2                      8.628 (3.644--20.429)    \<0.001        --                       --
  CHA~2~DS~2~-VASc score                                                                    
   1                       1.303 (0.320--5.300)     0.712          --                       --
   ≥2                      4.472 (1.315--15.214)    0.016          --                       --
  MS score                                                                                  
   1--2                    3.526 (1.016--12.230)    0.047          2.502 (0.681--9.188)     0.167
   ≥3                      23.000 (6.554--80.720)   \<0.001        14.698 (3.907--55.290)   \<0.001

*OR*: Odds ratio; *CI*: Confidence interval; LA: Left atrial; LAA: Left atrial appendage; AF: Atrial fibrillation; TIA: Transient ischemic attack; TG: Triglyceride; TC: Total cholesterol; HDL-C: High-density lipoprotein cholesterol; LDL-C: Low-density lipoprotein cholesterol; MS: Metabolic syndrome; DM: Diabetes mellitus; --: Not available.

Multivariate logistic regression model included age, gender, BMI, CHF, HBP, DM, previous stroke/TIA, vascular diseases, TG ≥150 mg/dl, TC ≥200 mg/dl, HDL-C \<40 mg/dl, LDL-C ≥130 mg/dl, MS, and CHADS~2~ and CHA~2~DS~2~-VASc categories. The results showed that previous stroke/TIA (*OR* = 1.991, *P* = 0.001), LA \>35 mm (*OR* = 2.823, *P* = 0.008), and MS score ≥3 (*OR* = 14.698, *P* \< 0.001) were independent risk factors for LA/LAA thrombus formation. Interestingly, traditional high-risk categories of stroke classified by CHADS~2~ score ≥2 or CHA~2~DS~2~-VASc score ≥2 were not associated with LA/LAA thrombus formation.

Relationship between the left atrial/left atrial appendage thrombus and risk scores {#sec2-8}
-----------------------------------------------------------------------------------

For the stroke risk stratification of CHADS~2~, CHA~2~DS~2~-VASc, and MS scores, the prevalence of LA/LAA thrombus increased with elevated risk scores \[Figure [1a](#F1){ref-type="fig"}, [1c](#F1){ref-type="fig"}, and [1e](#F1){ref-type="fig"}\], and statistically significant trends were found (all *P* \< 0.001). Similar to CHADS~2~ and CHA~2~DS~2~-VASc scores, the prevalence of LA/LAA thrombus also increased in line with elevated CHADS~2~-MS and CHA~2~DS~2~-VASc-MS scores (both *P* \< 0.001). For CHADS~2~-MS score, the minimum rate of thrombus was 2.9% when CHADS~2~-MS score = 0 and the maximum was 100% when CHADS~2~-MS score ranged from 7 to 8 \[[Figure 1f](#F1){ref-type="fig"}\]. Similarly, the minimum rate of thrombus was 0 when CHA~2~DS~2~-VASc-MS score = 0 and the maximum was 100% when CHA~2~DS~2~-VASc-MS score ranged from 9 to 10 \[[Figure 1g](#F1){ref-type="fig"}\]. The prevalence of LA/LAA thrombus also increased significantly with ascending CHADS~2~ or CHA~2~DS~2~-VASc risk categories (both *P* ≤ 0.001) \[Figure [1b](#F1){ref-type="fig"} and [1d](#F1){ref-type="fig"}\].

![The prevalence (percentage) of the left atrial or left atrial appendage thrombus formation for CHADS~2~, CHA~2~DS~2~-VASc, MS, CHADS~2~-MS, and CHA~2~DS~2~-VASc-MS scores and their corresponding categories. The prevalence (percentage) of the left atrial or left atrial appendage thrombus formation for CHADS~2~ score (a) and CHADS~2~ category (b); for CHA~2~DS~2~-VASc score (c) and CHA~2~DS~2~-VASc category (d); for MS score (e); for CHADS~2~-MS score (f); and CHA~2~DS~2~-VASc-MS score (g).](CMJ-129-2395-g001){#F1}

Comparisons of the predictive powers for the risk of the left atrial/left atrial appendage thrombus formation among CHADS~2~, CHA~2~DS~2~-VASc, MS, CHADS~2~-MS, and CHA~2~DS~2~-VASc-MS scores {#sec2-9}
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The C-statistics of CHADS~2~, CHA~2~DS~2~-VASc, MS, CHADS~2~-MS, and CHA~2~DS~2~-VASc-MS was 0.726, 0.710, 0.776, 0.807, and 0.792, respectively \[[Table 3](#T3){ref-type="table"} and [Figure 2](#F2){ref-type="fig"}\]. All the risk scores had moderate predictive powers for the risk of LA/LAA thrombus. There were no significant differences among the C-statistics of CHADS~2~, CHA~2~DS~2~-VASc, and MS scores in predicting LA/LAA thrombus. However, the C-statistics of CHADS~2~-MS score was significantly higher than those of CHADS~2~ score (0.807 vs. 0.726, *P*~CM-C~ = 0.0019), and the C-statistics of CHA~2~DS~2~-VASc-MS score was also significantly higher than those of CHA~2~DS~2~-VASc score (0.792 vs. 0.710, *P*~CM-C~ = 0.0007). These results suggested that the predictive power of CHADS~2~ score for the risk of LA/LAA thrombus was improved after mixing the MS score, and so was the CHA~2~DS~2~-VASc score.

###### 

Comparisons of C-statistics and 95% *CI*s for the risk of LA/LAA thrombus among CHADS~2~, CHA~2~DS~2~-VASc, MS, CHADS~2~-MS, and CHA~2~DS~2~-VASc-MS scores

  Variables             C-statistics   95% *CI*       *P* for C-statistics   *P*~CM-C~   *P*~CM-M~
  --------------------- -------------- -------------- ---------------------- ----------- -----------
  CHADS~2~              0.726          0.671--0.776   \<0.001                --          --
  CHA~2~DS~2~-VASc      0.710          0.654--0.761   \<0.001                --          --
  MS                    0.776          0.724--0.822   \<0.001                --          --
  CHADS~2~-MS           0.807          0.757--0.851   \<0.001                0.0019      0.2827
  CHA~2~DS~2~-VASc-MS   0.792          0.741--0.837   \<0.001                0.0007      0.6625

*P* for C-statistics: *P* value for area under the curve of each score; *P*~CM-C~: *P* value for the comparison of C-statistics between the CHADS2-MS score and the CHADS~2~ score or between the CHA~2~DS~2~-VASc-MS score and the CHA~2~DS~2~-VASc score; *P*~CM-M~: *P* value for the comparison of C-statistics between the CHADS~2~-MS score and the MS score or between the CHA~2~DS~2~-VASc-MS score and the MS score; *CI*s: Confidence intervals; LA: Left atrial; LAA: Left atrial appendage; --: Not available.

![Receiver operating characteristic (ROC) curves of predictive abilities of the risk of the left atrial or left atrial appendage thrombus formation by the CHADS~2~, CHA~2~DS~2~-VASc, MS, CHADS~2~-MS, and CHA~2~DS~2~-VASc-MS scores.](CMJ-129-2395-g002){#F2}

ROC curve analyses indicated that the optimal cutoff points of CHADS~2~-MS and CHA~2~DS~2~-VASc-MS scores in predicting thrombus were both ≥3 \[[Table 4](#T4){ref-type="table"}\]. Compared with CHADS~2~-MS score, CHA~2~DS~2~-VASc-MS score ≥3 was more sensitive in predicting LA/LAA thrombus formation (0.877 vs. 0.714) and had a lower negative predictive value (0.23 vs. 0.36). However, it was less specific than CHADS~2~-MS score (0.555 vs. 0.786) in predicting LA/LAA thrombus. The positive predictive value of CHA~2~DS~2~-VASc-MS score was also lower (1.96 vs. 3.33).

###### 

Sensitivity, specificity, PPV, and NPV of CHADS~2~-MS and CHA~2~DS~2~-VASc-MS scores ≥3 for predicting TEE risk factors

  Variables             Sensitivity   Specificity   PPV    NPV
  --------------------- ------------- ------------- ------ ------
  CHADS~2~-MS           0.714         0.786         3.33   0.36
  CHA~2~DS~2~-VASc-MS   0.877         0.555         1.96   0.23

PPV: Positive predictive value; NPV: Negative predictive value; TEE: Transesophageal echocardiography.

Additive effect of the metabolic syndrome score on the CHADS~2~ and CHA~2~DS~2~-VASc risk categories in predicting the left atrial or left atrial appendage thrombus formation {#sec2-10}
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Since the CHADS~2~-MS and CHA~2~DS~2~-VASc-MS scores were superior in predicting LA/LAA thrombus formation, we attempted to investigate whether the thrombotic risk was increased when additional MS components (high BMI, high level of TG, and low level of HDL-C) were added to the CHADS~2~ and CHA~2~DS~2~-VASc scores. The prevalence of LA/LAA thrombus for patients with 0--3 additional MS scores in conventional low-stroke risk group (CHADS~2~ or CHA~2~DS~2~-VASc scores = 0), moderate-risk group (CHADS~2~ or CHA~2~DS~2~-VASc scores = 1), and high-risk group (CHADS~2~ or CHA~2~DS~2~-VASc scores ≥2) is shown in [Figure 3](#F3){ref-type="fig"}. In the low-risk group, the thrombotic prevalence of patients who had three additional MS scores was 50.0% for CHADS~2~ category and 33.3% for CHA~2~DS~2~-VASc category, which were both higher than the high-risk group without any additional MS score (30.0% for CHADS~2~ category and 16.5% for CHA~2~DS~2~-VASc category). In addition, additional MS scores increased the prevalence of LA/LAA thrombus in each conventional risk category. All the patients in the high-stroke risk group with three additional MS scores suffered from LA/LAA thrombi.

![The prevalence (percentage) of the left atrial or left atrial appendage thrombus formation classified by additional MS score in low-, moderate-, and high-risk categories of CHADS~2~ (a) and CHA~2~DS~2~-VASc scores (b).](CMJ-129-2395-g003){#F3}

D[iscussion]{.smallcaps} {#sec1-4}
========================

In this study, we evaluated the additive effect of MS on risk stratification for LA/LAA thrombus formation in patients with NVAF and low CHADS~2~ and CHA~2~DS~2~-VASc scores. We found that MS was an independent risk factor for LA/LAA thrombus. Both CHADS~2~-MS and CHA~2~DS~2~-VASc-MS scores had better predictive powers for the risk of LA/LAA thrombus than CHADS~2~ and CHA~2~DS~2~-VASc scores, respectively.

LA/LAA thrombus detected by TEE is considered a risk for stroke in NVAF. The patients with LA/LAA thrombi were associated with 7.8% of the stroke per year and had 2.5-fold increase in thromboembolic events as compared with those without thrombi.\[[@ref13][@ref14]\] In comparison with the other conventional risk factors such as HBP, DM, CHF, and previous stroke, LA/LAA thrombus was a visible marker of AF-related stroke and a direct evidence for anticoagulant therapy. The CHADS~2~ and CHA~2~DS~2~-VASc scores were recommended for predicting the risk of stroke or thromboembolic events for NVAF patients,\[[@ref15][@ref16]\] and both of them were associated with TEE risk factors for thromboembolism.\[[@ref17]\]

The vast majority of epidemiological and observational studies suggested that individuals with MS had a greater likelihood of AF than their non-MS counterparts.\[[@ref18][@ref19][@ref20]\] Furthermore, Tsai *et al*.\[[@ref8]\] found that MS was also associated with the increased thromboembolic rate of NVAF patients. Our results showed that a graded positive association between the increasing number of MS components and the elevated rate of LA/LAA thrombus was identified, which was similar to the previous outcomes stated above. Previous pathophysiologic findings detected a possible link between MS and thromboembolism due to abnormal fibrinolysis, inflammation, and endothelial dysfunction. In patients with MS, the plasma level of fibrinogen, Factor VII, and Factor VIII was increased and the level of plasminogen activator inhibitor-1 was decreased, which resulted in a prothrombotic or hypercoagulable state.\[[@ref21]\] Another possible mechanism was that MS was a state of chronic inflammation with increased inflammatory factors, which induced atrial structural and electrical remodeling.\[[@ref22]\] Finally, all the components of MS contributed to the impairment of endothelial function, and AF led to a decreased antithrombotic ability in the damaged atrial endocardium and thus promoting thrombogenesis.\[[@ref23]\] In brief, NVAF patients with MS are more prone to developing a prothrombotic state and undergoing thromboembolic events than those without MS. The more components of MS someone has, the higher risk for him/her to have an LA/LAA thrombus.

A new scoring scheme called CHADS~2~-MS score which was established by Tsai *et al*.\[[@ref8]\] has a better predictive power for thromboembolism risk compared to CHADS~2~ score. In our study, we evaluated the predictive power of this new scoring system for the risk of LA/LAA thrombus formation. In fact, the CHADS~2~-MS score improved the predictive power of CHADS~2~ score for the risk assessment of LA/LAA thrombus, and the situation was the same for the CHA~2~DS~2~-VASc-MS score. In addition, our analysis showed that NVAF patients with CHADS~2~ or CHA~2~DS~2~-VASc score of 0 or 1 and three additional MS scores had a significantly higher prevalence of LA/LAA thrombus compared with those who had the same CHADS~2~ or CHA~2~DS~2~-VASc score but without MS. All the above-mentioned findings suggested that the additional MS score was complimentary to the CHADS~2~ or CHA~2~DS~2~-VASc score. High additional MS score could help identify patients at a high risk of developing stroke in the low-risk group stratified by the CHADS~2~ or CHA~2~DS~2~-VASc score.

As we know, the key pathogenesis of MS is insulin resistance. All the components of MS are related to each other by insulin resistance. Besides, chronic inflammatory reaction, impairment of endothelial function, and hypercoagulable state related to LA/LAA thrombus are associated with insulin resistance. The more severe the degree of insulin resistance is, the more components of MS the patients will develop. Several studies proved that higher mortality of cerebro-cardiovascular disease was in line with the increasing components of MS,\[[@ref24][@ref25]\] and MS was associated with an increased prevalence of AF.\[[@ref20]\] Although there was no previous report on the relationship between the number of MS components and LA/LAA thrombus formation, our observation provided novel evidence that there was a positive correlation between MS score and the prevalence of LA/LAA thrombus, and it might be a reasonable explanation for the improvement of predictive power for the risk of LA/LAA thrombus by adding MS scores.

In general, MS not only increases the predictive power of CHADS~2~ and CHA~2~DS~2~-VASc scores for the risk of LA/LAA thrombus, but also identifies individuals at a high risk of LA/LAA thrombus in low-stroke risk group classified by CHADS~2~ or CHA~2~DS~2~-VASc score. Anticoagulant therapy should be strengthened for the NVAF patients with higher additional MS score.

Our study also had several limitations. First, the sample size of this study was relatively small. In addition, most studies have chosen stroke or thromboembolic event as a major end point. LA/LAA thrombus might be a surrogate marker of stroke or thromboembolic events; however, it could not represent the prevalence of stroke or thromboembolic events completely. Finally, the CHADS~2~-MS or CHA~2~DS~2~-VASc-MS scoring system should also be evaluated in Caucasian and other Asian populations. A further follow-up would be needed to assess their actual predictive powers on stroke and thromboembolic events.

MS is an independent risk factor for LA/LAA thrombus formation in NVAF patients. Because the CHADS~2~-MS and CHA~2~DS~2~-VASc-MS scores can both identify individuals at a high risk of LA/LAA thrombus in low-stroke risk population classified by CHADS~2~ and CHA~2~DS~2~-VASc scores, they are superior to the CHADS~2~ and CHA~2~DS~2~-VASc scores in the risk stratification for LA/LAA thrombus formation. The present findings may help identify and control the risk factors for LA/LAA thrombus, thus preventing the occurrence of stroke and thromboembolism events.

Financial support and sponsorship {#sec2-11}
---------------------------------

This study was supported by the National Natural Science Foundation project (No.81670364) and Natural Science Foundation of Guangdong Province (No. 2016A030313356).

Conflicts of interest {#sec2-12}
---------------------

There are no conflicts of interest.

**Edited by:** Li-Min Chen
